Quantum Biopharma Ltd. (NASDAQ:QNTM - Free Report) - Stock analysts at Singular Research issued their Q1 2026 earnings per share estimates for Quantum Biopharma in a research note issued to investors on Wednesday, June 18th. Singular Research analyst G. Sriharan expects that the company will earn ($0.07) per share for the quarter. Singular Research currently has a "Moderate Buy" rating on the stock. The consensus estimate for Quantum Biopharma's current full-year earnings is ($3.27) per share. Singular Research also issued estimates for Quantum Biopharma's Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.53) EPS.
Separately, Wall Street Zen upgraded Quantum Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th.
Check Out Our Latest Stock Analysis on Quantum Biopharma
Quantum Biopharma Stock Down 13.3%
Shares of QNTM traded down $3.25 during mid-day trading on Monday, reaching $21.12. The company had a trading volume of 408,382 shares, compared to its average volume of 940,363. Quantum Biopharma has a 52-week low of $2.70 and a 52-week high of $38.25. The stock has a market capitalization of $61.46 million, a P/E ratio of -1.32 and a beta of 0.55. The stock has a 50 day moving average of $13.31 and a two-hundred day moving average of $8.22.
Quantum Biopharma (NASDAQ:QNTM - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($1.04). The firm had revenue of $2.09 million during the quarter, compared to analysts' expectations of $2.09 million.
Hedge Funds Weigh In On Quantum Biopharma
A hedge fund recently raised its stake in Quantum Biopharma stock. AdvisorShares Investments LLC boosted its holdings in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM - Free Report) by 163.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 69,078 shares of the company's stock after purchasing an additional 42,845 shares during the quarter. AdvisorShares Investments LLC owned approximately 3.60% of Quantum Biopharma worth $254,000 at the end of the most recent reporting period. 1.24% of the stock is owned by hedge funds and other institutional investors.
About Quantum Biopharma
(
Get Free Report)
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.
Recommended Stories
Before you consider Quantum Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quantum Biopharma wasn't on the list.
While Quantum Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
